EVH – European Vaccines Hub for Pandemic Readiness
Enhancing Health Preparedness Across Europe
EVH (European Vaccines Hub) for Pandemic Readiness is a pan-European center, dedicated to strengthening Europe’s capacity to rapidly develop safe, effective, and scalable vaccines in response to future global health crises.
The project is coordinated by the Sclavo Vaccines Association and structured in four strategic pillars:
- Discovery (led by Fondazione Biotecnopolo di Siena, Italy);
- Preclinical Studies (led by Institut Pasteur, France);
- Clinical Studies (led by Vaccinopolis – Universit of Antwerpen, Belgium);
- Regulation & Manufacturing (led by German Center for Infection Research – DZIF and Center for Pandemic Vaccines and Therapeutics – ZEPAI, Germany).
EVH brings together 11 Beneficiaries and 13 Affiliated and Associated entities from 7 European countries, promoting collaboration across academia, industry, and regulatory bodies.
Running from March 2025 to February 2029, EVH has a total budget of over 160 million euros, including 100 million euros in co-funding from the European Union’s EU4Health Program.
iBET’s Participation in EVH
iBET participates in Pillar 4 – Regulation & Manufacturing, coordinated by DZIF and ZEPAI. We are working with partner ZEPAI on activities within this pillar’s work packages that will culminate in a comprehensive technology transfer roadmap. This roadmap will outline conditions and recommendations for efficient technology transfers, including GMP and regulatory considerations, and will serve as a reference for the Health Emergency and Response Authority (HERA) and EVH partners.
Co-funded by the European Union through the EU4Health programme (EU4H-2024-PJ-01-1).